Innate Pharma (IPHA) News Today $2.13 +0.04 (+1.91%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 16, 2024 | americanbankingnews.comInnate Pharma (NASDAQ:IPHA) Shares Down 4.7% June 17, 2024 | businesswire.comInnate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 TrialJune 12, 2024 | marketbeat.comInnate Pharma (NASDAQ:IPHA) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $11.50 price target on shares of Innate Pharma in a report on Wednesday.June 4, 2024 | businesswire.comInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis FungoidesMay 28, 2024 | businesswire.comInnate Pharma Announces Its Participation in Upcoming Investor ConferencesMay 24, 2024 | businesswire.comInnate Pharma Highlights Abstracts Selected for ASCO 2024 Annual MeetingMay 23, 2024 | businesswire.comOutcome of Innate Pharma's 2024 Annual General MeetingMay 21, 2024 | businesswire.comInnate Pharma: Clarification Regarding SAR443579 DesignationMay 16, 2024 | markets.businessinsider.comInnate Pharma Buy Rating Affirmed Amid Robust Pipeline and Financial StabilityMay 15, 2024 | marketbeat.comInnate Pharma (NASDAQ:IPHA) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $11.50 price objective on shares of Innate Pharma in a report on Wednesday.May 15, 2024 | businesswire.comInnate Pharma Highlights Abstracts Selected for EHA 2024 CongressMay 14, 2024 | finance.yahoo.comInnate Pharma Reports First Quarter 2024 Business Update and Financial ResultsMay 14, 2024 | businesswire.comInnate Pharma Reports First Quarter 2024 Business Update and Financial ResultsMay 8, 2024 | marketbeat.comInnate Pharma (IPHA) Scheduled to Post Quarterly Earnings on TuesdayInnate Pharma (NASDAQ:IPHA) will be releasing earnings before the market opens on Tuesday, May 14, Zacks reports.May 7, 2024 | businesswire.comInnate Pharma Announces Conference Call and Webcast for Q1 2024 Business UpdateApril 15, 2024 | businesswire.comInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer PatientsApril 15, 2024 | businesswire.comInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024April 11, 2024 | marketbeat.comInnate Pharma's (IPHA) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $11.50 target price on shares of Innate Pharma in a research note on Thursday.April 10, 2024 | businesswire.comInnate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug ConjugateApril 9, 2024 | finance.yahoo.comInnate Pharma Announces Its Participation in Upcoming Investor ConferenceApril 9, 2024 | businesswire.comInnate Pharma Announces Its Participation in Upcoming Investor ConferenceApril 5, 2024 | finance.yahoo.comInnate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-FApril 5, 2024 | businesswire.comInnate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-FApril 2, 2024 | marketbeat.comInnate Pharma S.A. (NASDAQ:IPHA) Short Interest Up 13.6% in MarchInnate Pharma S.A. (NASDAQ:IPHA - Get Free Report) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 89,100 shares, a growth of 13.6% from the February 29th total of 78,400 shares. Based on an average daily volume of 11,700 shares, the short-interest ratio is presently 7.6 days.March 23, 2024 | seekingalpha.comInnate Pharma S.A. (IPHA) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | finance.yahoo.comInnate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | marketbeat.comInnate Pharma (NASDAQ:IPHA) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $11.50 price target on shares of Innate Pharma in a research report on Friday.March 21, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma Reports Full Year 2023 Financial Results and Business UpdateMarch 21, 2024 | businesswire.comInnate Pharma Reports Full Year 2023 Financial Results and Business UpdateMarch 19, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma Announces Its Participation to Upcoming Investor ConferenceMarch 19, 2024 | businesswire.comInnate Pharma Announces Its Participation to Upcoming Investor ConferenceMarch 14, 2024 | businesswire.comInnate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial ResultsMarch 6, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024March 6, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's LymphomaMarch 6, 2024 | finance.yahoo.comInnate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s LymphomaMarch 6, 2024 | businesswire.comInnate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's LymphomaMarch 6, 2024 | businesswire.comInnate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024February 21, 2024 | businesswire.comInnate Pharma Announces Its Participation to Upcoming Investor ConferenceJanuary 30, 2024 | marketbeat.comInnate Pharma (NASDAQ:IPHA) Trading Up 0.4%Innate Pharma (NASDAQ:IPHA) Shares Up 0.4%January 12, 2024 | finance.yahoo.comNumber of Shares and Voting Rights of Innate Pharma as of January 1, 2024January 4, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical ProgramJanuary 4, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive BoardJanuary 4, 2024 | finance.yahoo.comInnate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive BoardJanuary 3, 2024 | marketbeat.comInnate Pharma S.A. (NASDAQ:IPHA) Short Interest UpdateInnate Pharma S.A. (NASDAQ:IPHA - Get Free Report) was the recipient of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 54,000 shares, a drop of 5.9% from the November 30th total of 57,400 shares. Based on an average daily volume of 21,100 shares, the short-interest ratio is presently 2.6 days.December 31, 2023 | seekingalpha.comIPHYF Innate Pharma S.A.December 19, 2023 | morningstar.comInnate Pharma SA ADRDecember 18, 2023 | msn.comInnate Pharma CEO Mahjoubi to leave companyDecember 1, 2023 | benzinga.comInnate Pharma Stock (NASDAQ:IPHA), Analyst Ratings, Price Targets, PredictionsDecember 1, 2023 | benzinga.comInnate Pharma Stock (NASDAQ:IPHA) Dividends: History, Yield and DatesNovember 17, 2023 | markets.businessinsider.comPromising Clinical Outcomes and Strategic Partnerships Reinforce Buy Rating for Innate Pharma Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here IPHA Media Mentions By Week IPHA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPHA News Sentiment▼0.440.61▲Average Medical News Sentiment IPHA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPHA Articles This Week▼21▲IPHA Articles Average Week Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: REPL News RGNX News ADPT News EXAI News DNA News ITOS News ALEC News PROK News VALN News FATE News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IPHA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.